Entries by Ayal Ronen

FREEMIND is pleased to announce its sponsorship and invite you to attend Venture Summit | New England being held on December 9th, 2015.

FREEMIND is pleased to announce its sponsorship and invite you to attend Venture Summit | New England being held on December 9th, 2015. ***Special discount – use discount code ” Freemindvip” and receive an additional 10% off of the registration fee! Venture Summit | New England ™ December 9th, 2015 | Hilton, Boston Dedham  Where Innovation Meets Capital Friends, […]

/0 Comments/by

Webinar: Cancer Non Dilutive Funding Opportunities

NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well. In the upcoming webinar in the series of summer educational webinars FreeMind experts will discuss key cancer […]

/0 Comments/by

Biotech and Money New York 2015 – 17 November 2015

Venue: TKP New York Conference Center Location (city and country): New York, US Event Website Biotech and Money New York provides the education, strategies and solutions executives need to enable more effective funding, investment, business planning, partnering and strategic decision making within their business. It’s where life science meets money, investors meet deal flow and industry promote […]

/0 Comments/by

Webinar: CNS / PNS related Non Dilutive Funding Opportunities

Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical. In the webinar in the series of summer educational webinars FreeMind […]

/0 Comments/by

Webinar: Medical Device Non-Dilutive Funding: Trends & Opportunities

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage […]

/0 Comments/by

Webinar: U Mechanisms, cooperative agreements with the NIH

The U-Mechanism is a support mechanism used when there will be substantial Federal scientific or programmatic involvement by granting agency. Substantial involvement means that, after award, scientific or program staff will assist, guide, coordinate, or participate in project activities. We are seeing many programs utilizing this type of mechanism, with substantial awards being made to […]

/0 Comments/by

Webinar: Non-Dilutive funding for Non-US applicants

Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations […]

/0 Comments/by

FreeMind is Proud to Support the RESI Conference on September 16th – Boston

Life Science Nation (LSN) and Johnson & Johnson Innovation, JLABS (JLABS) are inviting fundraising life science companies to attend the upcoming Redefining Early Stage Investments (RESI) Conference in Boston on September 16th.   The first RESI Conference took place on September 16, 2013, and two years later, following highly successful events in San Francisco and Houston, LSN returns to Boston for the sixth […]

/0 Comments/by

Funding beyond the SBIR/STTR; RO1s and R21s for Companies

Every year NIH alone awards over $120,000,000 via R’-Mechanisms, among them the RO1 or R21. In order to maximize your funding potential all sources of funding must be considered including the less traditional sources. R21s aim to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas […]

/0 Comments/by